The FDA Just Approved a Stronger Wegovy — Here Is What Changed
On March 19, 2026, the FDA approved Wegovy HD — a once-weekly injectable semaglutide at 7.2mg, triple the previous maximum dose of 2.4mg. It was the first GLP-1 medication approved under the Commissioner's National Priority Voucher pilot program, which fast-tracked the review timeline.
The clinical numbers are hard to ignore. In the STEP UP trial of 1,407 adults with obesity and no diabetes, patients on semaglutide 7.2mg lost an average of 20.7% of their body weight over 72 weeks. Approximately one in three patients (33.2%) achieved 25% or greater weight loss — a threshold that was previously only reachable through bariatric surgery or the highest doses of tirzepatide.
Who Is Eligible for the Higher Dose?
Wegovy HD is not a first-line treatment. The FDA approval specifies that it is indicated for adults with obesity who have already tolerated the 2.4mg dose for at least four weeks and for whom additional weight reduction is clinically indicated. This is a step-up option, not a starting point.
In practical terms, this means your doctor may consider Wegovy HD if you have been on standard Wegovy for several months, have tolerated it well, and have either plateaued or have not yet reached your treatment goals. It is delivered via a new single-dose pen that launched in April 2026.
The Safety Signal You Should Know About
Important Safety Information:
In the STEP UP trial, dysesthesia (altered skin sensations such as tingling, numbness, or burning) occurred in 22% of patients on the 7.2mg dose, compared to 6% at 2.4mg and 0.3% on placebo. While generally mild and not a reason most patients discontinued, this is a notable new side effect that was not prominent at lower doses.
Otherwise, the safety profile was consistent with what clinicians already see with GLP-1 medications: nausea, diarrhea, vomiting, and constipation as the most common adverse events. Gastrointestinal discontinuation rates were modestly higher at 7.2mg (3.3%) versus 2.4mg (2.0%).
How Wegovy HD Compares to Other Options
| Medication | Type | Avg. Weight Loss | Key Difference |
|---|---|---|---|
| Wegovy HD 7.2mg | Injectable, weekly | 20.7% | Highest semaglutide dose, step-up only |
| Wegovy 2.4mg | Injectable, weekly | ~15-17% | Standard maximum semaglutide dose |
| Wegovy Pill 25mg | Oral, daily | ~14-17% | First oral GLP-1 for weight loss |
| Zepbound (tirzepatide) | Injectable, weekly | ~20-22% | Dual GLP-1/GIP agonist |
| Orforglipron | Oral, daily | ~7.5-11% | No food/water restrictions |
Questions to Ask Your Doctor
If you are currently on Wegovy 2.4mg and interested in the higher dose, here is what to discuss at your next appointment:
- Am I a candidate? You need to have tolerated 2.4mg for at least four weeks. If you had significant GI side effects at that dose, the 7.2mg may amplify them.
- What are my treatment goals? If you have already reached a healthy weight range and are in maintenance, the higher dose may not be appropriate. It is designed for patients who need additional weight reduction.
- What about the skin sensation side effects? Ask specifically about dysesthesia — what it feels like, when to report it, and whether it is a reason to discontinue.
- How does insurance handle this? Wegovy HD is available through the same channels as standard Wegovy, but prior authorization requirements may differ. Your prescriber's office should verify coverage before switching.
- Could I switch to tirzepatide instead? For some patients, switching medication classes may produce better results than increasing the dose of the same medication. This is a clinical decision that depends on your individual response.
Ready to Talk to a Doctor About GLP-1 Medication?
These telehealth providers offer consultations with licensed prescribers. Compare options and find one that fits your needs.
Compare Providers →